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1. INTRODUCTION 
 
1.1. PARKINSON’S DISEASE AND PARKINSONISMS: DIFFERENTIAL 
DIAGNOSIS 
 
Parkinsonism is defined by the association of bradykinesia with either hypertonia, resting 
tremor, or postural instability. The main cause of parkinsonism is idiopathic Parkinson’s 
disease (PD), a neurodegenerative disorder with a progressive (but not exclusive) loss of 
dopaminergic neurons. PD is characterized by asymmetrical parkinsonism, progressive 
worsening and initial benefit from levodopa. PD is primarily a disease of the elderly. Its 
prevalence increases with age from about 0.9% among persons 65 to 69 years old to 5% 
among persons 80 to 84 years old, with a slight male preponderance (de Rijk et al, 1997). 
Only a small percentage of patients, mostly with the genetic forms of PD, develop 
parkinsonism before the age of 45 years. In the absence of a reliable diagnostic marker, the 
clinical diagnosis of PD is based on the presence of characteristic features. Several diagnostic 
criteria have been developed for PD, including the U.K. Parkinson’s Disease Society Brain 
Bank criteria used in various clinical-pathologic studies (Hughes et al, 1992 a) (Hughes et al, 
1992 b). In 1999, a set of diagnostic criteria for PD was proposed, based on a review of the 
literature regarding the sensitivity and specificity of the characteristic clinical features (Gelb 
et al, 1999). The reliability of the different diagnostic criteria, however, has not been 
vigorously tested by autopsy examination, which is commonly considered the gold standard. 
Two separate clinical-pathologic series concluded that only 76% of patients with a clinical 
diagnosis of PD actually met the pathologic criteria; the remaining 24% had evidence of other 
causes of parkinsonism. One of the studies was based on autopsied brains collected from 100 
patients who had been clinically diagnosed with PD by the U.K. Parkinson’s Disease Society 
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Brain Bank (Hughes et al, 1992 a) (Hughes et al, 1992 b), and the other study consisted of 
autopsy examinations of brains from 41 patients who were followed prospectively by the 
same neurologist over a 22-year period (Rajput et al, 1991). In a study of 143 cases of 
parkinsonism that came to autopsy and had a clinical diagnosis made by neurologists, the 
positive predictive value of the clinical diagnosis was 98.6% for PD and 71.4% for the other 
parkinsonian syndromes (Hughes et al, 2002). In the DATATOP study, 800 patients were 
prospectively followed by trained parkinsonologists from early, untreated stages of clinically 
diagnosed PD for a mean of 7.6 years (Jankovic et al, 2000). An analysis of autopsy data, 
imaging studies, response to levodopa, and atypical clinical features indicated an 8.1% 
inaccuracy of initial diagnosis of PD by Parkinson experts. Although this is considerably less 
than the diagnostic error rate reported previously, the final diagnosis was not based on 
pathologic confirmation in all cases. In another study on a small cohort of patients, clinical 
diagnosis had changed in 33% of patients after a median follow-up of 29 months. Most (82%) 
changes occurred in the first year and were due to the development of atypical clinical 
features, particularly early cognitive impairment; the results of brain imaging; responsiveness 
to levodopa; and the rate of disease progression (Caslake et al, 2008). Much of the difficulty 
in the diagnosis of PD is in differentiating it from other disorders that cause parkinsonism. 
These include other neurodegenerative disorders such as dementia with Lewy bodies (DLB), 
progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal 
degeneration (CBD) and non-degenerative causes such as vascular parkinsonism or drug 
induced parkinsonism (e.g., as a result of antidopaminergic drugs). Features particularly 
useful in differentiating PD from other parkinsonian disorders include: absence or paucity of 
tremor, early gait abnormality (such as freezing), postural instability, pyramidal tract findings 
and poor response to levodopa. Therefore, while improvement with levodopa supports the 
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atypical parkinsonisms. At disease onset, the evolution of different features can be quite 
variable and, consequently, the differential diagnosis of each form of parkinsonism and its 
prognosis is often difficult for clinicians. Changing between different parkinsonian syndromes 
will alter what information is given to the patient about prognosis. Further research, in larger 
groups and over longer periods, is necessary to identify factors that may improve the accuracy 
of diagnosis at the initial assessment. 
 
1.2. SLEEP DISTURBANCES IN PD AND ATYPICAL PARKINSONISMS 
 
Neurodegenerative disease characterized by parkinsonism may present a variety of non-motor 
features, such as sleep disturbances, cognitive impairment, autonomic dysfunctions and 
olfactory deficit. Sleep disturbances are common non-motor symptoms in parkinsonian 
patients. The prevalence of sleep disorders in PD is reportedly 40% to 90% (Suzuki et al, 
2011). The sleep disturbances observed in patients are not specific to PD and include 
insomnia, excessive daytime sleepiness (EDS), sleep-disordered breathing (SDB), restless 
legs syndrome (RLS), periodic leg movements during sleep (PLMS) and rapid eye movement 
(REM) sleep behaviour disorder (RBD). Sleep problems in PD and atypical parkinsonisms are 
multifactorial and the mechanisms of the sleep disturbances are not fully known, but they 
probably include a clear interaction between drug and disease. Mechanisms of sleep 
disturbances in patients include rigidity and bradykinesia hindering turning in bed, the effects 
of dopaminergic medications, age-related changes, and changes integral to the disease itself. 
Dopaminergic drugs are known to have sleep-inducing properties at low doses while 
promoting wakefulness at high doses (Chaudhuri and Logishetty, 2009). Changes in the 
brainstem may occur early in the course of disease, affecting neurotransmitters that play a role 
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in arousal and wakefulness. Sleep problems are more common and more severe in atypical 
parkinsonisms than in PD. 
 
1.2.1. INSOMNIA 
 
Insomnia is defined as a recurrent difficulty falling asleep or staying asleep, with daytime 
psychological or cognitive consequences (International Classification of Sleep Disorders -
ICSD, 2005). Insomnia is common in all forms of parkinsonism. A community-based survey 
determined that 60.3% of patients with PD had a sleep problem, a substantially higher 
proportion than in patients with diabetes mellitus (45%), or in elderly controls (33%) 
(Tandberg et al, 1998). As many as 52.5% of patients with MSA have complained of sleep 
fragmentation, compared to 38.7% patients with PD (Ghorayeb et al, 2002). The most severe 
and specific insomnia is observed in patients with PSP (Arnulf et al, 2005) (Sixel-Döring et 
al, 2009). Sleep monitoring does not provide additional information on the cause of insomnia 
in parkinsonian patients, except for a specific, severe decrease of REM sleep in patients with 
PSP (Montplaisir et al, 1997). Insomnia is a non-specific symptom that does not necessarily 
result from a selective lesion in any sleep system, except in the case of PSP, in which 
brainstem cholinergic lesions can encompass the REM sleep executive systems (De Cock et 
al, 2008). The frequency of insomnia increases with advanced motor stages of PD and a need 
for a higher daily dose of dopaminergic therapy, an indicator of dopamine denervation. 
Indeed, slowed movements during the night, difficulties turning in bed, pain, cramps, 
nocturnal and early morning dystonia, and a frequent need to pass urine, are reported by 
patients with advanced PD as the main cause of their insomnia (De Cock et al, 2008). The 
majority of studies show no increase in arousal in PD patients, while nocturnal awakenings 
may be increased in PD and are influenced by dopaminergic drugs (Peeraully et al, 2012). 
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General factors, such as aging, anxiety, and depression, can account for some nocturnal sleep 
disruption in PD. Poor sleep quality correlates with depression and anxiety scores (Borek et 
al, 2006).  
 
1.2.2. EXCESSIVE DAYTIME SLEEPINESS  
 
EDS is defined as a disabling trend to doze or fall asleep in various circumstances (e.g. 
reading, as a passenger in a car, during a meeting) that interferes with family, professional, 
and social life. Daytime sleepiness in PD can be self-reported, but is better referred by 
caregivers, because some patients are unaware of being abnormally sleepy. Case-control 
epidemiological studies performed in various countries consistently found higher sleepiness 
scores and a higher incidence (range 16-74%, but usually around 33%) of abnormal 
somnolence in PD patients than in age-matched and sex-matched controls (De Cock et al, 
2008). EDS is associated with more advanced disease, higher doses of levodopa-equivalent, 
and sometimes the use of dopamine agonists (De Cock et al, 2008). The most worrying aspect 
of sleepiness in PD is sleep attacks, or sudden onsets of sleep without prodrome, first been 
described in patients using the new non-ergot dopaminergic drugs pramipexole and ropinirole 
(Frucht et al, 1999). Examples of sleep attacks include patients falling asleep during 
stimulating life conditions, such as eating a meal (the head drooping over the plate), walking, 
at work, carrying a child on an escalator, and, the most dangerous situation, while driving a 
car. The percentage of PD patients having experienced sleep attacks varies from 1 to 14%, 
and 1% to 4% PD patients report having experienced sleep attacks while driving (De Cock et 
al, 2008). A “narcolepsy-like” pattern of sleepiness (multiple sleep-onset REM periods) was 
found in PD: in a series of 54 PD patients, Arnulf et al found that more than half would fall 
asleep within, on average, 5 minutes, indicating pathological sleepiness; moreover, 41% of 
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sleepy patients fell directly into REM sleep at least twice, an abnormal pattern mostly 
observed in primary narcolepsy (Arnulf et al, 2002). The mechanisms of sleepiness and sleep 
attacks in PD can include a complex drug-and-disease interaction. Most arousal systems are 
affected by neuronal loss and Lewy bodies in PD brains, including the norepinephrine 
neurons in the locus coeruleus, the serotonin neurons in the raphe, the cholinergic neuron in 
the basal forebrain, and the hypocretin (orexin) neurons (also affected in primary narcolepsy) 
in the hypothalamus. By contrast, the wake-active dopamine neurons in the ventral 
periaqueductal grey matter and the histamine neurons in the hypothalamus are intact in PD 
brains (De Cock et al, 2008). In PD, sleepiness may be more common in patients with 
advanced disease. Sleep apnoea, PLMS, and sleep fragmentation do not correlate with the 
severity of daytime sleepiness, suggesting they do not contribute much to the mechanisms of 
sleepiness. The use of dopaminergic drugs exposes PD patients to a twofold to threefold 
higher risk of sleep attacks and points toward the sedative role of dopamine agonists in some 
PD patients. The risk of sleep attacks is similar using ergot agonists (bromocriptine, 
pergolide) or non-ergot agonists (pramipexole, ropinirole). The risk increases with higher 
daily dosage and decreases with drug withdrawal. By contrast, levodopa is more rarely 
sedative. Why drugs that are supposed to stimulate the alerting brain system (and do so when 
given at bedtime) are, on the contrary, sedative is as yet unknown. This effect cannot be 
explained, at these high doses, by the biphasic effect (presynaptic sedative effect at low dose, 
postsynaptic alerting effect at high dose) of dopamine agonists described in animals (De Cock 
et al, 2008). The sedation observed in selective PD patients suggests a genetic vulnerability to 
this side-effect of dopamine agonists, although sleepiness does not correlate with genetic 
variants of the enzyme responsible for dopamine catabolism (Arnulf et al, 2005) (De Cock et 
al, 2008). EDS may also affect patients with atypical parkinsonism, such as DLB, MSA, and 
PSP. The SLEEMSA study (Moreno-López et al, 2011) compared consecutive MSA patients 
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with PD patients and healthy subjects, matched for age and sex, to assess the frequency and 
associations of EDS in MSA. EDS was present in 28% of patients with MSA, 29% of patients 
with PD, and 2% of healthy subjects. Unlike PD, the amount of dopaminergic treatment in 
MSA was not correlated with EDS. Disease severity was weakly correlated with EDS in MSA 
and PD. RLS occurred in 28% of patients with MSA, 14% of patients with PD, and 7% of 
healthy subjects. Multiple regression analysis showed that SDB and sleep efficiency predicted 
EDS in MSA and the amount of dopaminergic treatment and presence of RLS in PD 
(Moreno-López et al, 2011). A “narcolepsy-like” pattern of sleepiness (multiple sleep-onset 
REM periods) was also found, although less frequently than in PD, in some cases of MSA 
and DLB, but not in PSP (Arnulf et al, 2005) (De Cock et al, 2008).  
 
1.2.3. SLEEP BREATHING DISORDERS  
 
Sleep apnoea has been inconsistently associated with PD. In early, untreated PD, the 
occurrence of sleep apnoea did not differ from that in normal age-matched controls (Ferini-
Strambi et al, 1992) (Wetter et al, 2000), and 31% of patients with PD assessed by 
polysomnography were shown to have sleep apnoea (Ferini-Strambi et al, 1992). Among 54 
sleepy patients with more advanced PD referred to a sleep laboratory, 20% had moderate to 
severe sleep apnoea (Arnulf et al, 2002). Comparing a series of 100 PD patients (50 
unselected consecutive patients matched for age, sex and body mass index and 50 patients 
referred for sleepiness) with 50 in-hospital controls, all evaluated by video-polysomnography 
(VPSG), sleep apnoea (defined as an apnoea-hypopnoea index greater than 5) was less 
frequent in the PD group (27%) than in the control group (40% in-hospital controls). 
Furthermore, only 10% of all PD patients had severe sleep apnoea. Sleep apnoea was not 
associated with increased sleepiness, nocturia, depression, cognitive impairment or 
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cardiovascular events in PD patients. Patients with PD did not display sleep hypoventilation, 
stridor or abnormal central sleep aponea (De Cock et al, 2010). These frequencies, obtained in 
a large group of PD patients followed in a tertiary care Movement Disorders Unit, are lower 
than those obtained in three smaller series, showing that 10/15 patients (Maria et al, 2003), 
21/49 patients (Diederich et al, 2005) and 7/9 sleepy patients (Dhawan et al, 2006) had sleep 
apnoea. These series include patients specifically referred for sleep monitoring, while 50 of 
De Cock’s unselected patients were consecutively recruited without selection bias. Although 
it is not clear whether obstructive sleep apnoea is more common in PD than in age-matched 
controls, it is of interest that most studies reporting sleep apnoea note that the body mass 
index (BMI) of patients with PD who have obstructive sleep apnoea/hypopnoea syndrome 
(OSAS) is not increased (Arnulf et al, 2002) (Diederich et al, 2005), in contrast to the general 
population in which an increased body mass index is a strong predictor for obstructive sleep 
apnoea (Schäfer et al, 2002). SDB may be less prevalent in PD than in other parkinsonian 
disorders like MSA in which OSAS occurs in 15% to 37% of the cases (Ferini-Strambi and 
Marelli, 2012) (Vetrugno et al, 2004). In MSA, many of areas involved in the automatic 
control of respiration are damaged (Benarroch, 2003) and the damage may cause central sleep 
apnoea, Cheyne–Stokes respiration during sleep and wakefulness, dysrhythmic breathing 
patterns, such as cluster breathing with periods of apnoea, apneustic breathing, and periodic 
inspiratory gasps. The stridor, that consists in an upper airway obstruction of the glottic 
aperture in the larynx because of partial or complete vocal cord abduction restriction, has 
been reported in 30%–42% of MSA cases (Iranzo et al, 2000) (Vetrugno et al, 2004) (Glass et 
al, 2006). Sleep apnoea is also frequent in DLB, in which OSAS occurs in 15% to 55% of 
cases (Terzaghi et al, 2013) (Pao et al, 2013). 
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1.2.4. REM BEHAVIOUR DISORDER  
 
RBD is a parasomnia characterized by vigorous dream-enacting behaviours, associated with 
nightmares and abnormal increased phasic and/or tonic electromyographic (EMG) activity 
during REM sleep (Iranzo et al, 2009) (Boeve, 2010). According to the second edition of the 
ICSD, a clinical diagnosis of RBD can only be made when a patient displays violent, 
potentially violent or sleep-disruptive dream-enactment behaviour along with REM sleep 
without atonia (RWA) as determined by VPSG. RBD may be idiopathic (iRBD) or secondary 
to neurological diseases, particularly those with involvement of the brainstem such as MSA, 
PD and DLB. In patients with neurodegenerative disorders, the onset of RBD may either 
antedate or follow the onset of parkinsonism, cerebellar syndrome, dysautonomia, and 
cognitive impairment. Several studies have shown that patients with iRBD have an increased 
risk of developing neurodegenerative diseases such as parkinsonism or dementia, with risk 
estimates of 20% to 45% after 5 years (Iranzo et al, 2006) (Postuma et al, 2009) (Sixel-Döring 
et al, 2011). RBD often antedates the full-blown clinical presentation of several 
neurodegenerative diseases, suggesting that this sleep disorder should be considered part of 
the neurodegenerative process rather than a predisposing factor (Iranzo et al, 2009). The exact 
cause of RBD in parkinsonism is mostly unknown, but a non-dopaminergic lesion of the 
system controlling atonia during REM sleep is highly suspected (Boeve et al, 2007). 
 
1.2.4.1. RBD in PD 
 
When diagnosis is based solely on clinical history, the prevalence of RBD in PD varies from 
15% to 46% (Iranzo et al, 2009). When diagnosis of RBD is established using clinical and 
VPSG criteria, the prevalence of RBD in PD patients ranges between 46% and 58% (Iranzo et 
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al, 2009). The Montreal group demonstrated that 33% of consecutive unselected patients with 
PD met the diagnostic criteria of RBD based on VPSG (Gagnon et al, 2002). Recently, 46% 
of a cohort of 457 PD patients with sleep disturbances was found to have RBD (Sixel-Döring 
et al, 2011). Most of these studies involved patients in different stage of disease and who had 
already been treated with dopaminergic drugs. Plomhause and colleagues reported on the 
frequency of RBD in newly diagnosed dopaminergic treatment-naïve PD patients: in their 
sample of 57 patients, 30% met the criteria for RBD (Plomhause et al, 2013), demonstrating 
that RBD is common early in the course of PD. The main strength of this study was its focus 
on analysing newly diagnosed PD patients prior to dopaminergic treatment with a relatively 
short duration of parkinsonism, with an average of 11 months and 15 months in PD-RBD and 
PD-no RBD patients, respectively, in contrast to previous studies with an average of PD 
duration over five years. Additional strengths included rigorous dual-night VPSG controlling 
for first-night effect and the use of well-accepted standardized methods for quantifying RWA 
metrics. Another study involving 20 consecutive patients with untreated early PD found a 
significantly higher percentage of RWA in PD patients compared to controls, but RBD was 
diagnosed in only one patient (Bušková et al, 2011). A prospective longitudinal single center 
observational cohort study of de novo PD patients and matched neurologically healthy 
controls investigating non-motor features and potential biomarkers in PD (“DeNoPa cohort”) 
showed that 40/158 PD patients (25%) and 2/110 controls (2%) had RBD. This large study 
identified a significantly higher prevalence of movement events in REM sleep (all motor 
behaviours and/or vocalizations with a purposeful component, seemingly expressive of a 
subject’s mentation, classified as “REM sleep behavioural events”, including minor 
movements such axial movements, small movements in the distal extremities, facial 
movements with or without vocalizations as well as violent behaviours) in PD patients (51%) 
compared to controls (15%), not yet fulfilling the entire spectrum of violent RBD or 
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classification of RBD according to ICSD (Mollenhauer et al, 2013). Literature data suggest 
that RBD may be associated with a specific RBD subtype. Patients with the tremor-
predominant form of PD (usually a more benign form of the disease) have RBD less often 
than those with the bradykinetic-hypertonia form (Postuma et al, 2008). Several teams 
examined the question of whether patients with PD plus RBD would be more cognitively 
impaired than those without RBD. Numerous cross-sectional studies have shown that patients 
with RBD have increased cognitive impairment on neuropsychological testing. Among 110 
patients with PD, the subgroup with clinical RBD had impaired executive functioning, 
compared to the group without RBD or hallucinations. This cognitive decline was more 
marked (with additional impairment of memory and logical abilities) in the presence of 
hallucinations (Sinforiani et al, 2006). A recent prospective study found that RBD was 
associated with an increased risk of dementia (Postuma et al, 2012). All patients had a VPSG 
at baseline. Over a mean 4-year follow-up, the incidence of dementia was assessed in those 
with or without RBD at baseline using regression analysis, adjusting for age, sex, disease 
duration, and follow-up duration; 42 patients were included in the full analysis. Twenty-seven 
patients had baseline RBD, and 15 did not. Four years after the initial evaluation, 48% with 
RBD developed dementia, compared to 0% of those without. All 13 patients who developed 
dementia had mild cognitive impairment on baseline examination. RBD at baseline also 
predicted the new development of hallucinations and cognitive fluctuations (Postuma et al, 
2012). Moreover, PD patients with RBD tended to have specific motor and non-motor 
manifestations, especially orthostatic hypotension (Postuma et al, 2008) (Romenets et al, 
2012). This indicates that RBD may be a marker of a relatively diffuse, complex subtype of 
PD. In PD, the brain structures modulating REM sleep such as the gigantocellularis reticularis 
nucleus, subcoeruleus region and amygdala are damaged, reflecting the high prevalence of 
RBD in this disease. The finding that RBD frequently occurs in the rigid-akinetic subtype of 
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disease may suggest that the ventrolateral region of the substantia nigra pars compacta is more 
severely damaged in these PD patients (Jellinger, 1999) (Iranzo et al, 2009).  
 
1.2.4.2. RBD in parkinsonisms 
 
RBD in MSA 
Most patients with MSA have RBD with a prevalence of 90.5-100% (Plazzi et al, 1997) 
(Iranzo et al, 2009). RBD is currently considered a red flag for the diagnosis of MSA (Gilman 
et al, 2008), and may be the first symptom of MSA. One study of 27 RBD patients found that 
RBD preceded the waking motor symptoms in 12 (44%) (Plazzi et al, 1997). Typically, 
VPSG shows a marked increase in submental tonic EMG activity during REM sleep which is 
greater than in iRBD and PD (Iranzo et al, 2009). In addition, phasic EMG activity is usually 
excessive in REM sleep. Brief episodes of sudden trunk and limb jerks during non-REM sleep 
were observed in a few MSA subjects with RBD, similar to but less complex than those 
occurring in the same patients during REM sleep (Iranzo et al, 2009). Aperiodic and periodic 
limb movements and excessive fragmentary myoclonus are also frequent in non-REM sleep. 
These non-REM sleep motor abnormalities in MSA patients with RBD are indicators of 
dissociated states of sleep, in which components of one state intrude into another (Iranzo et al, 
2009) (Vetrugno et al, 2009). The finding that brainstem cell loss in MSA is consistent and 
severe may explain the high prevalence of RBD in this disease.  
 RBD in DLB 
RBD is very common (approximately 70%) among patients with DLB and usually precedes 
the onset of dementia (Iranzo et al, 2009). The current consensus criteria for DLB consider 
RBD a suggestive feature of the disease (McKeith et al, 2005). The presence of RBD in a 
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patient with dementia supports the diagnosis of DLB against AD and other forms of cognitive 
impairment.  
RBD in PSP 
The first reported case of RBD in PSP was described in a 70-year old woman who 
parkinsonism developed one year before the onset of RBD (Pareja et al, 1996). In a series of 
15 PSP patients who underwent VPSG, 2 had clinical RBD and 4 had RWA (Arnulf et al, 
2005). In another study, 7 of 20 (35%) PSP patients had RBD (Sixel-Döring et al, 2009). 
These findings argue against RBD as an exclusive feature of the synucleinopathies.  
 
1.2.5. RESTLESS LEGS SYNDROME AND PERIODIC LEG MOVEMENTS IN 
SLEEP 
 
RLS is characterized by unpleasant urges to move the limbs, precipitated by rest, temporarily 
relieved by activity, and worse or exclusively present during evening hours (American 
Academy of Sleep Medicine, 2005). RLS is a very common disorder, affecting approximately 
10% of people over the age of 65 years (Rothdach et al, 2000), the prevalence increasing with 
aging. At least 80% of patients with RLS show PLMS (Montplaisir et al, 1997). PLMS are 
spontaneous sleep-related movements, frequently involving flexion of the toe, ankle, knee, 
and hip. Most patients experience repeated flexion of the lower extremities, but some 
complain of arm movements too. Each movement lasts 0.5 to 10 seconds and occurs at 
intervals of 5 to 90 seconds, with a remarkable periodicity of approximately 20 to 40 seconds 
(ICSD, 2005). Several studies have addressed the prevalence of RLS in the PD population: 
documented rates are between 8% and 20.8% (De Cock et al, 2008). A study of 126 PD 
patients and 128 healthy age-and sex-matched controls in India found RLS to be present in 10 
patients (7.9%) and 1 control (0.8%): PD patients with RLS were older and had a higher 
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prevalence of depression than those without RLS (Krishnan et al, 2003). Ondo and coworkers 
evaluated 303 PD patients and found 63 (20.8%) had symptoms of RLS. Neither PD patient 
demographics nor PD treatments could reliably predict the development of RLS symptoms. 
PD symptoms preceded RLS symptoms in 54 (68%) of 79 patients with PD/RLS. Compared 
with patients with idiopathic RLS, patients with PD/RLS were older at RLS onset, were less 
likely to have a family history of RLS, and had lower serum ferritin levels (Ondo et al, 2002). 
A study in the Japanese population (Nomura et al, 2006) also found a significantly higher 
prevalence of RLS in PD patients than in control subjects (12% vs. 2.3%).   
A cross-sectional study evaluated and compared sleep disturbances in patients with PD (16 
cases), MSA (13 cases), PSP (14 cases) and 12 controls. RLS was frequent (57%) and related 
to reduced sleep duration and efficiency in PSP. RLS was more frequent in PD and PSP, and 
in PSP it was associated with reduced sleep efficiency and sleep duration (Gama et al, 2010).  
Another study evaluated RLS prevalence in 187 consecutive patients with parkinsonian 
disorders (PD = 134, PSP = 27, MSA = 21, DLB = 5) and in 172 healthy controls. The 
prevalence of RLS was higher in patients compared to controls (9.6% vs. 2.9%; p = 0.009) 
and was highest in PD (11.9%). RLS was present in only one patient, each with MSA and 
PSP, and none with DLB (Bhalsing et al, 2013). The SLEEMSA study found that RLS 
occurred in 28% of patients with MSA, 14% of patients with PD, and 7% of healthy subjects 
(Moreno-López et al, 2011). The findings of a recent systematic review of case-control VPSG 
studies in PD (Peeraully et al, 2012) do not support an increased incidence of PLMS in PD 
patients compared with controls. Sixel-Döring and colleagues found significantly more PLMS 
in the PD patients with RBD versus the non-RBD PD group, with a mean hourly index of 35 
± 4 versus 22 ± 4 (Sixel-Döring et al, 2011). This finding is mirrored by the significantly 
increased PLM index in a group of patients with iRBD who eventually developed PD 
compared to patients with iRBD who remained idiopathic after 6 years of follow-up: 85.2 ± 
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44.8 vs 35.9 ± 21.1 (Schenck and Boeve, 2011). Motor-behavioural dyscontrol in PD is now 
shown to extend commonly across wakefulness, REM sleep (RWA/RBD) and non-REM 
sleep (PLMS), raising the possibility of a common pathogenesis. In MSA, PLMS is a frequent 
motor sleep disturbance (Iranzo et al, 2009) (Vetrugno et al, 2009): in one study, 88% of 19 
MSA patients showed PLMS (Vetrugno et al, 2004). Sixel-Döring and colleagues found that 
the PLMS and PLMW index were significantly higher in PSP than in PD patients (110.3±79.9 
vs 43.7± 47.8; 92.6± 61.0 vs 27.9± 30.8). Overall, PLM indices were >15 in 19/20 PSP 
patients and 15/20 PD patients (Sixel-Döring et al, 2009).   
 
1.3. AIMS OF THE STUDY 
 
Aim of this study is to describe the possible diagnostic value of sleep disturbances in the 
differential diagnosis of neurodegenerative diseases characterized by parkinsonian features at 
onset.  
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2. PATIENTS AND METHODS 
 
This project is part of the BO-ProPark study (Bologna-motor and non-motor Prospective 
study on Parkinsonisms at onset), a prospective longitudinal single centre observational study 
started in our Department (IRCCS Institute of Neurological Sciences, Bellaria Hospital, 
Bologna, Italy; Department of Biomedical and Neuromotor Sciences, University of Bologna, 
Italy) in September 2007. Sixty-five consecutive patients with parkinsonian features and 
disease duration up to 3 years, evaluated at the Movement Disorders Centre of our 
Department since January 2008, were consecutively enrolled. Forty-five patients were 
evaluated twice, at baseline (T0) and 16 months later (T1). Three patients did not complete 
the study. 
 
2.1. DIAGNOSTIC PROCEDURES 
 
All patients underwent the same evaluation including:  
-  clinical history and neurological examination 
-  neuroimaging studies ( brain MRI/TC ) 
-  evaluation of autonomic control of the cardiovascular system 
-  quantification of motor response to standard oral levodopa test 
-  neuropsychological testing 
UPDRS, Beck’s Depression Inventory (BDI), Epworth Sleepiness Scale (ESS), PD Sleep 
Scale (PDSS) 1, criteria for the diagnosis of RLS and RBD questionnaire, were administered. 
All clinical data useful for diagnosis of PD, MSA, PSP, DLB, CBD and symptomatic forms 
were described and tabulated with full details in a database developed ad hoc for this study.  
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Each patient was evaluated twice: the first study was performed at the time of recruitment, 
and the second study after 16 months. Clinical history was updated, with particular attention 
to sleep disorders and neurological examination. The appearance of comorbidity, the 
introduction of new medications for parkinsonism, cognitive and behavioural disturbances 
were evaluated. At the first evaluation, 10 patients were being treated with dopaminergic 
drugs (levodopa or dopamine agonists); one patient was being treated with amantadine. 
Dopaminergic drugs were withdrawn two weeks before sleep evaluation. The diagnosis was 
made at the second evaluation (T1), according to international diagnostic criteria (Gelb et al, 
1999; Emre et al, 2007; Litvan et al, 1996; Gilman et al, 2008; Lang et al, 1994; McKeith et 
al, 2005) (for international diagnostic criteria see Appendix 1). The patients were diagnosed 
as: 
- PD (Gelb et al, 1999); 
- PD plus, which included PD with dementia (PD-D) (Emre et al, 2007), PD with cognitive 
impairment but not dementia (CIND), in which cognitive functioning falls below normal but 
who do not meet dementia criteria, and PD with dysautonomia, with prominent neurogenic 
orthostatic hypotension (OH) defined as a fall in blood pressure of at least 20 mmHg systolic 
and 10 mmHg diastolic within 3 min in the upright position (Consensus Committee of the 
American Autonomic Society and the American Academy of Neurology, 1996);  
- parkinsonian syndromes (PS), including MSA (Gilman et al, 2008), PSP (Litvan et al, 
1996), DLB (McKeith et al, 2005), CBD (Lang et al, 1994) and PS not otherwise specified 
(when poorly levodopa-responsive parkinsonism occurs, without features suggestive to PSP, 
MSA, CDB or DLB).  
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2.2. NIGHT VPSG STUDY 
 
All patients underwent a full night VPSG including EEG (C3-A2, O2-A1, CZ-A1), right and 
left electro-oculogram (EOG), surface EMG of mentalis, bilateral wrist extensor and tibialis 
anterior muscles, EKG, microphone, oro-nasal, thoracic and abdominal respirograms, 
systemic arterial pressure, oxygen saturation and continuous audiovisual acquisition. A sleep 
laboratory technician monitored each recording. Sleep stages and tonic and phasic 
components of REM sleep were scored according to the American Academy of Sleep 
Medicine (AASM) criteria (Iber et al, 2007). According to ASSM and the ICSD (ICSD, 2005) 
criteria, we evaluated: 
-  arousal events: the number of arousals and the arousal index (AI) (index: number of 
events per hour of sleep); 
-  respiratory events: number of obstructive/central/mixed apnoeas/hypopnoeas and 
apnoea/hypopnoea index (AHI) 
-  movement events: PLMS, PLMS index, PLMS/arousal index; excessive fragmentary 
myoclonus (EFM), hypnic jerks (HJs) and RBD.  
PLMS and other simple (EFM, HJs) or complex motor events during sleep (RBD) were 
checked against the video recording. The tonic and phasic components of REM sleep were 
scored separately, according to AAMS criteria. Each 30-second epoch was scored as tonic or 
atonic depending on whether tonic chin EMG activity was present for more or less than 50% 
of the epoch. In each patient, phasic EMG activity was evaluated in mini-epochs of 3 seconds 
in all REM sleep periods; a phasic EMG event was defined as any burst of EMG activity 
lasting 0.1-5.0 seconds with an amplitude exceeding at least 4 times the background EMG 
activity. Each VPSG was scored by a neurologist blinded to the clinical diagnosis.  
This thesis will discuss only VPSG data of the first evaluation.  
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2.3. STATISTICAL ANALYSIS 
 
We compared PD (group 1: 27 patients) sleep data to PS+PD plus (group 2: 15 patients) sleep 
data (due to the small sample size, PD plus patients were included in the PS group).  
SPSS 12.0 (SPSS, Inc., Chicago, IL) was used for all statistical analyses. Descriptive statistics 
are given as means ± standard deviation or frequencies (percentages), as applicable.	 Kruskal 
Wallis test was used for comparison of quantitative variables among groups. Chi square (X2) 
test was used for the between-group comparison to test the association with PLMS disorder, 
RLS, RBD, EFM, HJs and EDS. A P-value p ≤ 0,05 was considered significant. 	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3. RESULTS 
 
3.1 PATIENTS’ DEMOGRAPHICS AND CLINICAL CHARACTERISTICS  
 
We analysed VPSG data of 42 consecutive patients (15 women; mean age at T0: 61±11 years; 
range: 37-79 years; mean disease duration at T0: 18±9 months; range: 5-36 months; mean age 
at onset of motor symptoms: 59±11 years; range: 35-78 years). At the second evaluation (T1) 
(mean age: 62 ±11 years; range 38-80 years; mean disease duration: 34±9 months; range: 21-
52 months), patients were diagnosed according to international diagnostic criteria as: 
- 27 PD: 10 women; mean age at onset of motor symptoms: 58±12 years (range: 35-78 years); 
mean age at T0: 60 ±12 years (range 37-79 years); mean disease duration at T0: 16±8 months 
(range: 5-36 months); mean age at T1: 61 ±12 years (range 38-80 years); mean disease 
duration at T1: 32±8 months (range 21-52 months). 
- 4 PD plus (2 PD with PD with dysautonomia; 1 PD with CI; 1 PD with dementia): 1 woman; 
mean age at onset of motor symptoms: 62±9 years (range: 55-76 years); mean age at T0: 63 
±9 years (range 58-77 years); mean disease duration at T0: 15±14 months (range: 7-36 
months); mean age at T1: 64 ±9 years (range 59-78 years); mean disease duration at T1: 
31±14 months (range 23-52 months). 
- 11 parkinsonian syndromes (PS), including PSP (2 patients), MSA (1 patient), CBD (1 
patient) and PS not otherwise specified (7 patients): 4 women; mean age at onset of motor 
symptoms: 60±9 years (range: 40-72 years); mean age at T0: 62 ±10 years (range 41-74 
years); mean disease duration at T0: 26±8 months (range: 12-36 months); mean age at T1: 63 
±10 years (range 42-75 years); mean disease duration at T1: 42±8 months (range 28-52 
months).  
Detailed data on patients’ clinical characteristics are summarized in Tables 1 and 2.  
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Table 1 Demographic characteristics of PD patients. PD: Parkinson disease; M: male; F: female. 
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Table 2 Demographic characteristics of PD plus and PS patients. PD: Parkinson disease; PS: parkinsonian 
syndrome; PDD: PD with dementia; PSP: progressive supranuclear palsy; MSA: multiple system atrophy; CBD:  
corticobasal degeneration; OH: orthostatic hypotension; CIND: cognitive impairment not dementia; M: male; F: 
female.  
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3.2. SLEEP QUESTIONNAIRE RESULTS AT THE FIRST EVALUATION (T0) 
 
3.2.1. RLS QUESTIONNAIRE 
36/42 (24/27 PD; 4/4 PD plus; 8/11 PS) patients completed the RLS questionnaire. RLS 
symptoms were present in 6/24 PD (25%) and in 6/12 (50%) PS+PD plus patients (2/4 PD 
plus; 4/8 of PS). There was no significant difference in RLS between the two groups (PD vs 
PS+PD plus: p=0.13).  
 
3.2.2. ESS 
37/42 (24/27 PD; 4/4 PD plus; 9/11 PS) completed the ESS. ESS score was >10 in 3 patients 
(2/24 PD, 1/9 PS) (p=0.80). No patients referred sleep attacks, even after dopaminergic 
treatment.  
 
3.3.3. PDSS-1 
38/42 (25/27 PD; 4/4 PD plus; 9/11 PS) patients completed PDSS-1. Total PDSS-1 score was 
123.3  ±	 17.5 in PD patients and 115.4  ±	 25.7 in PS+PD plus patients.  
For detailed data see Tables 3 and 4. 
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Table 3. Sleep questionnaire results of PD patients. RLS: restless legs syndrome; ESS: Epworth sleepiness 
scale; PDSS-1: PD Sleep scale. 
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Table 4. Sleep questionnaire results of PD plus and PS patients. RLS: restless legs syndrome; ESS: Epworth 
sleepiness scale; PDSS-1: PD Sleep scale. 
 
3.3. VPSG RESULT AT THE FIRST EVALUATION (T0) 
 
3.3.1. SLEEP PARAMETERS 
Sleep efficiency (SE) was reduced in all patients, with a mean value of 61±16% of total sleep 
time (TST) (normal value >85%). No difference in SE was seen between the two groups 
(mean value PD patients: 65.3±10.1% of TST; mean value PS+PD plus patient: 54.7±22.3% 
of TST) (p=0.112). Both groups showed a reduced TST (PD TST: 258 ± 49 min vs PS+PD 
plus TST: 213 ± 90 min; p=0.181). All sleep stages were represented (Stage 1: 5.5 ± 3.1% in 
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PD versus 8.1 ± 11.3% in PS+PD plus patients; p=0.990; Stage 2: 44.1 ± 12.3% in PD versus 
48.4 ± 13.3 % in PS+PD plus patients; p= 0.423; Stage 3: 31.5 ± 9.9% in PD versus 26.7 ± 
11.5% in PS+PD plus patients; p= 0.487; Stage REM: 18.9 ± 8.0% in PD versus 16.8 ± 9.7% 
in PS+PD plus patients; p=0.646). There was no significant difference in TST, sleep stage 
duration or percentages and sleep latency or between the two groups.  
Wake after sleep onset (WASO) was higher in PS+PD plus patients (43.6 ± 22.2%) (158.0 ± 
72.5 min) than in PD patients (30.7 ± 9.8%) (113.7 ± 36.5 min) (p=0.047) (p=0.032).  
For detailed results see Tables 5, 6 and 7.  
 
 
Table 5. Sleep parameters of PD patients and PS+ PD plus patients TST: total sleep time; WASO: wake 
after sleep onset; SE: sleep efficiency. 
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Table 6. PD patients’ sleep parameters. TST: total sleep time; WASO: wake after sleep onset; SE: sleep 
efficiency. 
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Table 7. PD plus and PS patients’ sleep parameters. TST: total sleep time; WASO: wake after sleep onset; 
SE: sleep efficiency. 
 
3.3.2. REM FEATURES  
REM latency was increased in all patients (124.9 ± 83.8 min): no difference was seen 
between PD (123.0 ± 73.0 min) and PS+PD plus patients (124.0 ± 102 min) (p=0.627). The 
mean percentage of epochs with enhanced tonic muscle EMG activity during REM sleep was 
higher in PD plus and PS (14 ± 33% of REM sleep epochs; range 0-100) than in PD patients 
(4 ± 15% of REM sleep epochs; range 0-78) (p=0.034). No difference in phasic muscle EMG 
activity during REM sleep was seen between the two groups (PD: 8 ± 17% of REM sleep 
epochs, range 0-72; PS+PD plus 12 ± 14% of REM sleep epochs, range 0-38) (p=0.335). 
RBD episodes were recorded in 7 patients (2/27 PD; 3/4 PD plus; 2/11 PS). Ten (4/27 PD, 3/4 
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PD plus, 3/11 PS) patients had a positive questionnaire for RBD: at least one RBD episode 
was recorded in 7/10 (2 PD, 3 PD plus, 2 PS). No RBD episodes were recorded in 1 PS 
patient (patient 3) with a positive questionnaire for RBD, but VPSG documented an excessive 
phasic muscle activity (35.7% of epochs) during REM sleep. In 2 PD patients (patient 26 and 
patient 39) with a positive questionnaire for RBD, VPSG documented a normal atonia during 
REM sleep and no RBD episodes were recorded. According to AASM criteria, the diagnosis 
of RBD was made in 2/27 (7.4%) PD patients and 6/15 (40%) PS and PD plus patients 
(p=0.01). In particular, in group 2 a diagnosis of RBD was made in 3/4 (75%) of PD plus 
patients and 3/11 (27%) of PS patients (1 PSP, 1 MSA, 1 PS not otherwise specified).   
Detailed data on patients’ REM sleep features are summarized in Tables 8, 9 and 10.  
 
 
Table 8. REM sleep features of PD patients and PS+ PD plus patients. 
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Table 9. PD patients’ REM sleep features. 
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Table 10. PD plus and PS patients’ REM sleep features. 
 
3.3.3. AROUSAL INDEX 
 
No difference in arousal index (AI) was seen between groups (AI in PD: 13.4 ±	 7, range 3.1-
35.9 versus AI in PS+ PD plus: 11.5 ±	 4.9, range 3.9-21.3) (p=0.572). For detailed results see 
Table 11.  
 
3.3.4. PLMS DISORDER AND OTHER SIMPLE MOTOR EVENTS DURING SLEEP 
 
No difference in PLMS index (PD: 40.6 ± 53.8 versus PS+PD plus: 37.2 ± 47.5; p=0.875), 
PLMS NREM sleep index (PD: 41.4 ± 53.6 versus PS+PD plus: 36.9± 48; p=0.885), PLMS 
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REM sleep index (PD: 37.1 ± 63.6 versus PS+PD plus: 36 ± 51.8; p = 0.812), PLMS/arousal 
index (PD: 3.9 ± 4.7 versus PS+PD plus: 1.9 ± 1.8; p = 0.492), PLMS/arousal NREM index 
(PD: 4.5 ± 5.7 versus PS+PD plus: 2.0 ± 2.0; p = 0.321) or PLMS/arousal REM index (PD: 
1.3 ± 3.1 versus PS+PD plus: 1.1 ± 2.1, p = 0.913) was seen between groups.   
The PLMS index was ≥ 15 in 16/27 (59%) PD patients and in 10/15 (66.6%) PS+PD plus 
patients. HJs were more frequent in PS+PD plus patients (5/15 patients, 33.3%) than in PD 
patients (2/27 patients, 7.4%) (p=0.03).  
No difference was seen between groups in EFM recorded in 3/27 (11.1%) PD patients and 
5/15 (33.3) PS + PD plus patients (p=0.06). For detailed results see Table 11. 
 
3.3.5. RESPIRATORY EVENTS DURING SLEEP  
 
The AHI was higher in PS + PD plus patients (AHI: 9 ± 13; range 0-35) than in PD patients 
(AHI: 5 ± 14; range 0-62)(p = 0.018). VPSG diagnosis of OSAS (AHI ≥ 10) was made in 4 
patients: 1/27 PD (3.7%) (patient 38: AHI = 30.9) and 3/15 PS patients (20%) (patient 8: 
AHI=16.25; patient 15: AHI=27.75; patient 37: AHI: 34.6) (p=0.08). Stridor was not detected 
in any patients. For detailed results see Table 11. 
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Table 11. Arousal, motor and respiratory events of PD patients and PS+ PD plus patient 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
37 
4. DISCUSSION 
 
We compared the VPSG features of 27 consecutive patients with PD and 15 consecutive 
patients with atypical parkinsonism (PS and PD plus patients) at disease onset. Our aim was 
to evaluate the possible diagnostic value of sleep disturbances in the differential diagnosis of 
neurodegenerative diseases characterized by parkinsonian features at onset. 
Our findings show a severely reduced SE and TST in all patients, with a significant increase 
in WASO in patients with atypical parkinsonisms (PS and PD plus) than in PD patients. No 
significant differences between groups of patients were detected in other sleep parameters.  
Analysing REM sleep features, we found that the mean percentage of epochs with enhanced 
tonic muscle EMG activity during REM sleep was higher in PD plus and PS than in PD. No 
difference in phasic muscle EMG activity during REM sleep was seen between the two 
groups. Moreover, RBD was more frequent in PD plus and PS than in PD patients: a 
diagnosis of RBD (according to AASM criteria) was made in 7.4% of PD patients and 40% of 
PS and PD plus patients (75% of PD plus patients and 27% of PS patients). These results 
suggest that RBD is rarely present in early untreated PD, whereas it is more common in PD 
associated with dysautonomia or CIND/dementia, also in the early stage of disease. These 
data seem to conflict with literature reports of a prevalence of RBD in PD patients ranging 
between 46% and 58% (Iranzo et al, 2009), but most of these studies involved patients in 
different disease stages who had already been treated with dopaminergic drugs. Few VPSG 
studies involved newly diagnosed dopaminergic treatment-naïve PD patients: one study in 
untreated PD patients reported a RBD prevalence of 30%, not associated with CI (Plomhause 
et al, 2013), whereas another study found RBD rarely present in early untreated PD (only in 
1/20 PD patients) (Buskova et al, 2011). The DeNoPa cohort (Mollenhauer et al, 2013) made 
a diagnosis of RBD in 40/159 (25%) newly diagnosed drug naïve PD patients (disease 
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duration < 2 years, range 9-24 months): these patients underwent neuropsychological testing 
of executive functions, attention and speech, verbal fluency, memory and visuospatial 
function, but no autonomic tests were performed to evaluate possible OH. Moreover, no 
longitudinal patient data are available in the DeNoPa cohort, and patients with atypical PD at 
an early stage of their illness may have been included.  
Our results indicate that the presence of RBD at disease onset in PD patients would suggest 
the possible future appearance of cognitive or dysautonomic symptoms, as seen in PD plus 
patients, in agreement with literature data confirming that RBD in PD patients is associated 
with dementia and OH (Postuma et al, 2008) (Postuma et al, 2012) (Romenets et al, 2012). 
These results suggest that RBD may be a marker of a relatively diffuse and complex subtype 
of PD. Pathological changes in the brainstem structures modulating REM sleep, responsible 
for RBD and RWA, seem to be present earlier in PD plus and PS patients than in PD patients.  
HJs, brief and sudden trunk and limb jerks during NREM sleep, similar to but less complex 
than those occurring in the same patients during REM sleep, were observed in PD plus and PS 
patients more frequently than in PD patients. The same observation was reported by other 
authors (Iranzo et al, 2009) (Vetrugno et al, 2009) in patients with MSA, suggesting that these 
non-REM sleep motor abnormalities in MSA patients are indicators of dissociated states of 
sleep, in which components of one state intrude into another. Another explanation for these 
results might be that motor-behavioural dyscontrol in atypical parkinsonisms tends to extend 
across wakefulness, REM sleep (RWA/RBD) and NREM sleep (HJs), more frequently and/or 
earlier than in PD.  
Only 1/27 (3.7%) PD patients have OSAS versus 20% (3/15) of PS+PD plus patients whose 
AHI is higher than that of PD patients. Sleep apnoea does not seem to be clinically relevant in 
PD patients, while patients with atypical parkinsonisms (PS and PD plus) are a greater risk of 
developing disordered breathing events during sleep. These results are probably related to an 
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early and more marked damage of brain areas involved in the automatic control of respiration 
(Benarroch, 2003).  
RLS symptoms were present in 6/24 PD (25%) and in 6/12 (50%) PS+PD plus patients, 
substantially in agreement with literature data. 
EDS is not clinically relevant in our sample of patients, with ESS scores >10 in only three 
cases (2/24 PD, 1/9 PS). These frequencies are lower than those obtained in other studies, that 
included patients in different disease stages and often treated with dopamine agonists, 
whereas our patients were drug naïve and with recent onset of disease. These factors may 
explain the lower frequency of EDS in our group of patients.  
The main strength of this study is its focus on consecutively analysing newly diagnosed 
parkinsonian patients with a short disease duration prior to dopaminergic treatment. 
Moreover, the longitudinal follow-up of our cohort with serial VPSG provided opportunities 
to clarify the evolution of sleep disorders with disease progression in neurodegenerative 
diseases characterized by parkinsonian features. Another major strength of the study is that 
the diagnosis was not only clinical, but also instrumental: all patients underwent autonomic 
and neuropsychological tests, so the diagnosis of OH and dementia are well documented.  
We are aware of several limitations of our study, including:  
1) The lack of an age and gender matched control group, due to the difficulty in finding 
appropriate controls (healthy individuals, matched for age and gender). However, our aim was 
not to differentiate patients from controls, but to differentiate different groups of patients to 
disclose features useful for differential diagnosis;  
2) The lack of dual-night VPSG controlling the first-night effect;  
3) The small sample of patients, especially PS and PD plus patients.  
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5. CONCLUSIONS 
 
Our data suggest that REM sleep motor control (RWA/RBD) is more frequently impaired at 
disease onset in patients with PS and PD plus compared to PD patients. The presence of RBD 
or an enhanced tonic muscle EMG activity in a patient with recent onset parkinsonian features 
should suggest a diagnosis of atypical parkinsonism, rather than PD. More data are needed to 
establish the diagnostic value of these features in the differential diagnosis of parkinsonisms. 
The evaluation of sleep disorders, with an in-depth clinical interview followed by VPSG, may 
be a useful tool in the differential diagnosis of parkinsonism at onset. 
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APPENDIX 1 
 
 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
DIAGNOSTIC	  CRITERIA	  FOR	  PD	  (Gelb	  et	  al,	  1999)	  
GROUP	  A:	  Features	  characteristic	  of	  PD	  	  
	  
• Resting	  tremor	  	  
• Bradykinesia	  	  
• Rigidity	  	  
• Asymmetric	  onset	  	  
	  
GROUP	  B:	  Features	  suggestive	  of	  alternative	  diagnoses	  
• Features	  unusual	  early	  in	  the	  clinical	  course:	  prominent	  postural	  instability	  in	  the	  first	  3	  years	  after	  
symptom	  onset;	  
• freezing	  phenomena	  in	  the	  first	  3	  years;	  hallucinations	  unrelated	  to	  medications	  in	  the	  first	  3	  years;	  
dementia	  preceding	  motor	  symptoms	  or	  in	  the	  first	  year;	  	  
• supranuclear	  gaze	  palsy	  or	  slowing	  of	  vertical	  saccades;	  	  
• severe,	  symptomatic	  dysautonomia	  unrelated	  to	  medications;	  	  
• documentation	  of	  a	  condition	  known	  to	  produce	  parkinsonism	  and	  plausibly	  connected	  to	  the	  patient’s	  
symptoms	  (such	  as	  suitably	  located	  focal	  brain	  lesions	  or	  neuroleptic	  use	  within	  the	  past	  6	  months).	  
	  
POSSIBLE	  PD	  
	  
At	  least	  2	  of	  the	  4	  features	  in	  group	  A	  are	  present;	  	  
at	  least	  1	  of	  these	  is	  tremor	  or	  bradykinesia.	  	  
And	  either:	  	  
-­‐	  none	  of	  the	  features	  in	  group	  B	  is	  present	  or	  symptoms	  have	  been	  present	  for	  less	  than	  3	  years,	  and	  none	  of	  the	  
features	  in	  Group	  B	  is	  present	  to	  date	  	  
and	  either:	  	  
-­‐	  substantial	  and	  sustained	  response	  to	  levodopa	  or	  a	  dopamine	  agonist	  has	  been	  documented	  or	  patient	  has	  not	  
had	  an	  adequate	  trial	  of	  levodopa	  or	  dopamine	  agonist.	  
	  
PROBABLE	  PD	  
	  
At	  lest	  3	  of	  the	  4	  features	  in	  group	  A	  are	  present	  and	  none	  of	  the	  features	  in	  group	  B	  is	  present	  (note:	  symptom	  
duration	  of	  at	  least	  3	  years	  is	  needed	  to	  meet	  this	  requirement)	  and	  substantial	  and	  sustained	  response	  to	  
levodopa	  or	  a	  dopamine	  agonist	  has	  been	  documented.	  
	  
DEFINITE	  PD	  
	  
All	  criteria	  for	  POSSIBLE	  Parkinson	  disease	  are	  met	  and	  histopathological	  confirmation	  of	  the	  diagnosis	  is	  obtained	  
at	  autopsy.	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DIAGNOSTIC	  CRITERIA	  FOR	  PDD	  (Emre	  et	  al,	  2007)	  
I.	  Core	  features	  
Diagnosis	  of	  PD	  disease	  according	  to	  Queen	  Square	  Brain	  Bank	  criteria	  	  
A	  dementia	  syndrome	  with	  insidious	  onset	  and	  slow	  progression,	  developing	  within	  the	  context	  of	  established	  PD	  
and	  diagnosed	  by	  history,	  clinical,	  and	  mental	  examination,	  defined	  as:	  Impairment	  in	  more	  than	  one	  cognitive	  
domain	  	  representing	  a	  decline	  from	  premorbid	  level.	  	  
Deficits	  severe	  enough	  to	  impair	  daily	  life	  (social,	  occupational,	  or	  personal	  care),	  independent	  of	  the	  impairment	  
ascribable	  to	  motor	  or	  autonomic	  symptoms.	  
II.	  Associated	  clinical	  features	  
Cognitive	  features:	  Attention:	  Impaired.	  Impairment	  in	  spontaneous	  and	  focused	  attention,	  poor	  performance	  in	  
attentional	  tasks;	  performance	  may	  fluctuate	  during	  the	  day	  and	  from	  day	  to	  day.	  Executive	  functions:	  Impaired.	  
Impairment	  in	  tasks	  requiring	  initiation,	  planning,	  concept	  formation,	  rule	  finding,	  set	  shifting	  or	  set	  maintenance;	  
impaired	  mental	  speed	  (bradyphrenia).	  Visuospatial	  functions:	  Impaired.	  Impairment	  in	  tasks	  requiring	  visual-­‐spatial	  
orientation,	  perception,	  or	  construction.	  Memory:	  Impaired.	  Impairment	  in	  free	  recall	  of	  recent	  events	  or	  in	  tasks	  
requiring	  learning	  new	  material,	  memory	  usually	  improves	  with	  cueing,	  recognition	  is	  usually	  better	  than	  free	  recall.	  
Language:	  Core	  functions	  largely	  preserved.	  Word	  finding	  difficulties	  and	  impaired	  comprehension	  of	  complex	  
sentences	  may	  be	  present.	  
Behavioural	  features:	  Apathy:	  decreased	  spontaneity;	  loss	  of	  motivation,	  interest,	  and	  effortful	  behaviour	  	  Changes	  
in	  personality	  and	  mood	  including	  depressive	  features	  and	  anxiety.	  Hallucinations:	  mostly	  visual,	  usually	  complex,	  
formed	  visions	  of	  people,	  animals	  or	  objects.	  	  Delusions:	  usually	  paranoid,	  such	  as	  infidelity,	  or	  phantom	  boarder	  
(unwelcome	  guests	  living	  in	  the	  home)	  delusions.	  Excessive	  daytime	  sleepiness.	  
III.	  Features	  which	  do	  not	  exclude	  PD-­‐D,	  but	  make	  the	  diagnosis	  uncertain	  
Co-­‐existence	  of	  any	  other	  abnormality	  which	  may	  by	  itself	  cause	  cognitive	  impairment,	  but	  judged	  not	  to	  be	  the	  
cause	  of	  dementia,	  e.g.	  presence	  of	  relevant	  vascular	  disease	  in	  imaging.	  
Time	  interval	  between	  the	  development	  of	  motor	  and	  cognitive	  symptoms	  not	  known.	  
IV.	  Features	  suggesting	  other	  conditions	  or	  diseases	  as	  cause	  of	  mental	  impairment,	  which,	  when	  present	  make	  it	  
impossible	  to	  reliably	  diagnose	  PD-­‐D	  
-­‐	  Cognitive	  and	  behavioural	  symptoms	  appearing	  solely	  in	  the	  context	  of	  other	  conditions	  such	  as:	  Acute	  confusion	  
due	  to	  a.	  Systemic	  diseases	  or	  abnormalities	  b.	  Drug	  intoxication	  Major	  Depression	  according	  to	  DSM	  IV	  
-­‐	  Features	  compatible	  with	  “Probable	  Vascular	  dementia”	  criteria	  according	  to	  NINDS-­‐AIREN	  (dementia	  in	  the	  context	  
of	  cerebrovascular	  disease	  as	  indicated	  by	  focal	  signs	  in	  neurological	  exam	  such	  as	  hemiparesis,	  sensory	  deficits,	  and	  
evidence	  of	  relevant	  cerebrovascular	  disease	  by	  brain	  imaging	  AND	  a	  relationship	  between	  the	  two	  as	  indicated	  by	  
the	  presence	  of	  one	  or	  more	  of	  the	  following:	  onset	  of	  dementia	  within	  3	  months	  after	  a	  recognized	  stroke,	  abrupt	  
deterioration	  in	  cognitive	  functions,	  and	  fluctuating,	  stepwise	  progression	  of	  cognitive	  deficits)	  
	  
Probable	  PD-­‐D	  
A.	  Core	  features:	  Both	  must	  be	  present	  B.	  Associated	  clinical	  features:	  
•	  Typical	  profile	  of	  cognitive	  deficits	  including	  impairment	  in	  at	  least	  two	  of	  the	  four	  core	  cognitive	  domains	  
(impaired	  attention	  which	  may	  fluctuate,	  impaired	  executive	  functions,	  impairment	  in	  visuospatial	  functions,	  and	  
impaired	  free	  recall	  memory	  which	  usually	  improves	  with	  cueing)	  
•	  The	  presence	  of	  at	  least	  one	  behavioural	  symptom	  (apathy,	  depressed	  or	  anxious	  mood,	  hallucinations,	  delusions,	  
excessive	  daytime	  sleepiness)	  supports	  the	  diagnosis	  of	  Probable	  PD-­‐D,	  lack	  of	  behavioural	  symptoms,	  however,	  does	  
not	  exclude	  the	  diagnosis	  
C.	  None	  of	  the	  group	  III	  features	  present	  
D.	  None	  of	  the	  group	  IV	  features	  present	  
	  
Possible	  PD-­‐D	  
A.	  Core	  features:	  Both	  must	  be	  present	  B.	  Associated	  clinical	  features:	  
•	  Atypical	  profile	  of	  cognitive	  impairment	  in	  one	  or	  more	  domains,	  such	  as	  prominent	  or	  receptive-­‐type	  (fluent)	  
aphasia,	  or	  pure	  storage-­‐failure	  type	  amnesia	  (memory	  does	  not	  improve	  with	  cueing	  or	  in	  recognition	  tasks)	  with	  
preserved	  attention	  
•	  Behavioural	  symptoms	  may	  or	  may	  not	  be	  present	  OR	  
C.	  One	  or	  more	  of	  the	  group	  III	  features	  present	  	  
D.	  None	  of	  the	  group	  IV	  features	  present	  
  
 
43 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
DIAGNOSTIC	  CRITERIA	  FOR	  MSA	  (Gilman	  et	  al,	  2008)	  
PROBABLE	  MSA	  
	  A	  sporadic,	  progressive,	  adult	  (>30	  y)–onset	  disease	  characterized	  by	  	  
-­‐	  autonomic	  failure	  involving	  urinary	  incontinence	  or	  an	  orthostatic	  decrease	  of	  blood	  pressure	  within	  3	  min	  of	  
standing	  by	  at	  least	  30	  mm	  Hg	  systolic	  or	  15	  mm	  Hg	  diastolic	  and	  	  
-­‐	  poorly	  levodopa-­‐responsive	  parkinsonism	  (bradykinesia	  with	  rigidity,	  tremor,	  or	  postural	  instability)	  or	  
-­‐	  a	  cerebellar	  syndrome	  (gait	  ataxia	  with	  cerebellar	  dysarthria,	  limb	  ataxia,	  or	  cerebellar	  oculomotor	  dysfunction)	  
	  
POSSIBLE	  MSA	  
A	  sporadic,	  progressive,	  adult	  (>30	  y)–onset	  disease	  characterized	  by	  	  
-­‐	  parkinsonism	  or	  	  
-­‐	  a	  cerebellar	  syndrome	  	  and	  
-­‐	  at	  least	  one	  feature	  suggesting	  autonomic	  dysfunction	  	  and	  
-­‐	  at	  least	  one	  of	  the	  additional	  features	  	  	  
	  
Additional	  features	  of	  POSSIBLE	  MSA	  
	  
Possible	  MSA-­‐P	  or	  MSA-­‐C	  
	  
• Babinski	  sign	  with	  hyperreflexia	   	  
• Stridor	  
	  
Possible	  MSA-­‐P	  
	  
• Rapidly	  progressive	  parkinsonism	  
• Poor	  response	  to	  levodopa	  
• Postural	  instability	  within	  3	  years	  of	  motor	  onset	  
• Gait	  ataxia,	  cerebellar	  dysarthria,	  limb	  ataxia,	  or	  cerebellar	  oculomotor	  dysfunction	  
• Dysphagia	  within	  5	  years	  of	  motor	  onset	  
• Atrophy	  on	  MRI	  of	  putamen,	  middle	  cerebellar	  peduncle,	  pons,	  or	  cerebellum	  
• Hypometabolism	  on	  FDG-­‐PET	  in	  putamen,	  brainstem,	  or	  cerebellum	  
	   	  
Possible	  MSA-­‐C	  
	  
• Parkinsonism	  (bradykinesia	  and	  rigidity)	  
• Atrophy	  on	  MRI	  of	  putamen,	  middle	  cerebellar	  peduncle,	  or	  pons	   	  
• Hypometabolism	  on	  FDG-­‐PET	  in	  putamen	  
• Presynaptic	  nigrostriatal	  dopaminergic	  denervation	  on	  SPECT	  or	  PET	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DIAGNOSTIC	  CRITERIA	  FOR	  PSP	  (Litvan	  et	  al,	  1996)	  
POSSIBLE	  PSP	  	  
	  
Gradually	  progressive	  disorder	  with	  onset	  at	  age	  40	  or	  later.	  	  
Either	  vertical	  supranuclear	  palsy	  or	  both	  slowing	  of	  vertical	  saccades	  and	  prominent	  postural	  instability	  with	  falls	  in	  
the	  first	  year	  of	  onset.	  	  
No	  evidence	  of	  other	  diseases	  that	  can	  explain	  the	  clinical	  features,	  as	  indicated	  by	  mandatory	  exclusion	  criteria.	  	  
	  
PROBABLE	  PSP	  	  
	  
Gradually	  progressive	  disorder	  with	  onset	  at	  age	  40	  or	  later.	  	  
Vertical	  supranuclear	  palsy	  and	  prominent	  postural	  instability,	  with	  falls	  in	  the	  first	  year	  of	  disease.	  	  
No	  evidence	  of	  other	  diseases	  that	  can	  explain	  the	  clinical	  features,	  as	  indicated	  by	  mandatory	  exclusion	  criteria.	  	  
	  
Supportive	  criteria	  
	  
• Symmetric	  akinesia	  or	  rigidity,	  proximal	  more	  than	  distal	  
• Abnormal	  neck	  posture,	  especially	  retrocollis	  
• Poor	  or	  absent	  response	  of	  parkinsonism	  to	  levodopa	  therapy	  
• Early	  dysphagia	  and	  dysarthria	  
• Early	  cognitive	  impairment	  with	  at	  least	  2	  of	  the	  following:	  apathy,	  abstract	  thought	  impairment,	  decreased	  
verbal	  fluency,	  imitation	  behaviour,	  or	  frontal	  release	  signs.	  	  
	  
Mandatory	  exclusion	  criteria	  
	  
• Recent	  history	  of	  encephalitis	  
• Alien	  limb	  syndrome,	  cortical	  sensory	  deficits,	  focal	  frontal	  or	  temporoparietal	  atrophy.	  
• Hallucination	  or	  delusions	  unrelated	  to	  dopaminergic	  therapy	  
• Cortical	  dementia	  of	  Alzheimer’s	  type	  
• Prominent,	  early	  cerebellar	  symptoms	  or	  prominent,	  early	  unexplained	  dysautonomia	  
• Severe,	  asymmetric	  parkinsonian	  signs	  
• Neuroradiologic	  evidence	  of	  relevant	  structural	  abnormality	  
• Whipple	  disease’s,	  confirmed	  by	  polymerase	  chain	  reaction,	  if	  indicated	  
DIAGNOSTIC	  CRITERIA	  FOR	  CBD	  (Lang	  et	  al,	  1994)	  
Inclusion	  criteria	  
	  
Rigidity	  plus	  one	  cortical	  sign	  (apraxia,	  cortical	  sensory	  loss,	  or	  alien	  limb)	  or	  asymmetric	  rigidity,	  dystonia	  and	  focal	  
reflex	  myoclonus.	  
	  
Exclusion	  criteria	  
	  
Early	  dementia	  
Early	  vertical	  gaze	  palsy	  
Rest	  tremor	  
Severe	  autonomic	  disturbance	  
Sustained	  response	  to	  levodopa	  	  
Lesions	  on	  imaging	  studies	  indicate	  another	  pathological	  process	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DIAGNOSTIC	  CRITERIA	  FOR	  DLB	  (McKeith	  et	  al,	  2008)	  
Central	  features	  (essential	  for	  diagnosis	  of	  POSSIBLE	  and	  PROBABLE	  DLB)	  	  
	  
• Dementia,	  defined	  as	  progressive	  mental	  decline	  serious	  enough	  to	  interfere	  with	  normal	  daily	  activities.	  	  
• Prominent	  or	  persistent	  memory	  impairment	  may	  not	  necessarily	  occur	  in	  the	  early	  stage	  but	  is	  usually	  
evident	  with	  progression.	  	  
• Deficits	  on	  tests	  of	  attention,	  executive	  function,	  and	  visuospatial	  ability	  may	  be	  especially	  prominent.	  	  
	  
Core	  features	  (two	  core	  features	  are	  sufficient	  for	  diagnosis	  of	  PROBABLE	  DLB,	  one	  for	  POSSIBLE	  DLB)	  
	  
• Fluctuating	  cognition	  with	  pronounced	  variations	  in	  attention	  and	  alertness	  
• Recurrent	  visual	  hallucinations	  typically	  well-­‐formed	  and	  detailed	  
• Spontaneous	  features	  of	  parkinsonism	  
	  
Suggestive	  symptoms	  (if	  one	  or	  more	  of	  these	  is	  present	  in	  the	  presence	  of	  one	  or	  more	  core	  features,	  a	  diagnosis	  
of	  PROBABLE	  DLB	  can	  be	  made.	  In	  the	  absence	  of	  any	  core	  features,	  one	  or	  more	  suggestive	  symptoms	  is	  sufficient	  
for	  a	  diagnosis	  of	  POSSIBLE	  DLB)	  
	  
• RBD	  	  
• Severe	  neuroleptic	  sensitivity	  
• Low	  dopamine	  transporter	  uptake	  in	  basal	  ganglia	  demonstrated	  by	  SPECT	  or	  PET	  imaging.	  
	  
Supportive	  symptoms	  (commonly	  present	  but	  not	  proven	  to	  have	  diagnostic	  specificity)	  	  
	  
• Repeated	  falls	  and	  syncope	  
• Transient,	  unexplained	  loss	  of	  consciousness	  
• Severe	  autonomic	  dysfunction	  
• Hallucinations	  in	  other	  modalities	  
• Delusions	  
• Depression	  
• Relative	  preservation	  of	  medial	  temporal	  lobe	  structures	  on	  CT/MRI	  scan	  
• Generalized	  low	  uptake	  on	  SPECT/PET	  perfusion	  scan	  with	  reduced	  occipital	  activity	  
• Abnormal	  (low	  uptake)	  MIBG	  myocardial	  scintigraphy	  
• Prominent	  slow	  wave	  activity	  on	  EEG	  	  
	  
DLB	  should	  be	  diagnosed	  when	  dementia	  occurs	  before	  or	  concurrently	  with	  parkinsonism	  (if	  it	  is	  present).	  The	  
term	  PD	  dementia	  (PDD)	  should	  be	  used	  to	  describe	  dementia	  that	  occurs	  in	  the	  context	  of	  well-­‐established	  PD.	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